|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.95 EUR | -0.89% |
|
+3.30% | -5.84% |
| 04-22 | Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 04-05 | Boiron SA announces Annual dividend, payable on June 05, 2026 | CI |
| Market Cap | 490M 558M 451M 423M 792M 52.68B 809M 5.42B 2.1B 26.03B 2.1B 2.05B 90.27B | P/E 2024 |
41x | P/E 2025 | 16.1x |
|---|---|---|---|---|---|
| Enterprise Value | 442M 504M 407M 381M 715M 47.53B 730M 4.89B 1.89B 23.49B 1.89B 1.85B 81.45B | EV / Sales 2024 |
0.85x | EV / Sales 2025 | 0.95x |
| Free-Float |
19.96% | Yield 2024 |
4.48% | Yield 2025 | 4.46% |
| 1 week | +3.30% | ||
| Current month | +0.71% | ||
| 1 month | +2.92% | ||
| 3 months | +11.90% | ||
| 6 months | -6.00% | ||
| Current year | -5.84% |
| 1 week | 27 | 28.5 | |
| 1 month | 26.5 | 29 | |
| 3 years | 20.7 | 55.3 | |
| 5 years | 20.7 | 55.3 | |
| 10 years | 20.7 | 92.03 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Houdayer
CEO | Chief Executive Officer | 56 | 31/12/2024 |
Frédéric Riou
CTO | Chief Tech/Sci/R&D Officer | - | - |
Isabelle Chanel
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Thierry Boiron
CHM | Chairman | 65 | 30/06/2011 |
| Director/Board Member | 54 | 09/03/2010 | |
| Director/Board Member | 51 | 22/05/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.89% | +3.30% | +28.18% | -26.56% | 558M | ||
| -0.32% | -2.95% | -15.89% | -9.30% | 12.33B | ||
| -2.14% | -4.72% | -38.81% | -59.87% | 4.51B | ||
| -0.57% | -4.82% | -17.28% | -10.97% | 4.11B | ||
| -3.74% | -2.40% | +4.56% | -42.35% | 3.6B | ||
| -3.92% | -6.18% | +6.51% | -20.53% | 3.58B | ||
| -1.01% | -1.97% | -12.32% | -11.10% | 3.44B | ||
| -2.50% | -6.03% | -15.56% | -6.03% | 2.91B | ||
| -4.14% | -5.96% | -11.08% | -28.36% | 2.23B | ||
| 0.00% | -3.73% | -14.63% | +22.05% | 1.6B | ||
| Average | -2.04% | -3.70% | -8.63% | -19.30% | 4.26B | |
| Weighted average by Cap. | -1.66% | -3.69% | -13.44% | -19.41% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 488M 556M 449M 421M 789M 52.46B 805M 5.4B 2.09B 25.92B 2.09B 2.04B 89.89B | 501M 572M 462M 432M 811M 53.91B 828M 5.55B 2.15B 26.64B 2.15B 2.1B 92.39B |
| Net income | 11.34M 12.93M 10.45M 9.78M 18.34M 1.22B 18.72M 126M 48.6M 603M 48.55M 47.49M 2.09B | 32.64M 37.23M 30.09M 28.17M 52.82M 3.51B 53.92M 362M 140M 1.74B 140M 137M 6.02B |
| Net Debt | -49.74M -56.73M -45.85M -42.92M -80.49M -5.35B -82.16M -551M -213M -2.64B -213M -208M -9.17B | -47.86M -54.58M -44.11M -41.3M -77.44M -5.15B -79.05M -530M -205M -2.54B -205M -200M -8.82B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change |
|---|---|---|
| 29/06/26 | €27.80 | -1.42% |
| 26/06/26 | €28.20 | +2.17% |
| 25/06/26 | €27.60 | +0.73% |
| 24/06/26 | €27.40 | -1.79% |
| 23/06/26 | €27.90 | +1.82% |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BOI Stock
- BON Stock
Select your edition
All financial news and data tailored to specific country editions
















